IBJNews

Lilly depression drug fails to meet goals in studies

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. will end development of the depression medicine edivoxetine as an add-on therapy after the drug failed to meet goals in three studies.

A current trial evaluating the experimental compound’s long-term effects will continue, the Indianapolis-based company said in a statement Thursday.

Edivoxetine, a derivative of Lilly's Strattera drug for attention deficit disorder, was in the final of three stages of testing usually required for marketing approval by U.S. regulators.

The end of edivoxetine as a potential add-on therapy is another research setback for Lilly, which has had a cancer treatment, ramucirumab, fail in breast cancer patients, and an experimental compound prove unsuccessful in helping people with advanced Alzheimer’s disease. Lilly has cut costs and put resources into diabetes therapies as the company prepares for a revenue decline next year when it loses patent protection on antidepressant drug Cymbalta and osteoporosis medicine Evista.

According to Reuters, industry analysts had been hoping edivoxetine, if approved, would reach annual sales in the $200 million range by 2016 and even more in future years.

Edivoxetine had been expected to generate $560 million by 2020, said Seamus Fernandez, an analyst with Leerink Swann & Co., who has an outperform rating on the stock. Sales at that level would have made the drug Lilly’s 10th-biggest product last year.

The decision to end the development as an add-on therapy will result in a pretax charge of $15 million, or 1 cent a share, in the fourth quarter, Lilly said. The company reaffirmed its 2013 forecasts and said it is still plans to return to revenue growth in 2015.

Lilly shares were up 18 cents Thursday morning, to $50.04 each.

ADVERTISEMENT

  • maybe 'cannabis'
    I would recommend Lilly trying a cannabis based drug for depression, as it would be cheaper for research and development, and usually guaranteed to work.

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT